Thursday May 25th 2017

Sulfatide‐mediated control of extracellular matrix‐dependent oligodendrocyte maturation

In the central nervous system, the extracellular matrix (ECM) compound laminin‐2, present on developing axons, is essential in regulating oligodendrocyte (OLG) maturation. For example, laminin‐2 is involved in mediating interactions between integrins and growth factors, initially localizing in separate membrane microdomains. The galactosphingolipid sulfatide is an important constituent of these microdomains and may serve as a receptor for laminin‐2. Here, we investigated whether sulfatide interferes with ECM–integrin interactions and, in this manner, modulates OLG maturation. Our data reveal that disruption of laminin‐2–sulfatide interactions impeded OLG differentiation and myelin‐like membrane formation. On laminin‐2, but not on (re)myelination‐inhibiting fibronectin, su…

More here:  

Sulfatide‐mediated control of extracellular matrix‐dependent oligodendrocyte maturation

Leave a Comment

More from category

MS Study Alert: Share Your Thoughts About MS Research
MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS
Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS
First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows
Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint
Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]